A Pharmacodynamic/Pharmacokinetic Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus on Treatment With Lisinopril

Inclusion Criteria: * Adult male and female patients, 18 to 65 years of age, inclusive * Diabetes mellitus Type 2, diagnosed at least 3 months before screening * Treated with stable dose of metformin for at least 4 weeks prior to screening * Treated with stable dose of Angiotensin-converting enzyme inhibitor (ACEI) for at least 4 weeks prior to screening * Body mass index (BMI) 18 to 38 kg/m2, inclusive Exclusion Criteria: * Positive for HIV-1, HIV-2, hepatitis B or hepatitis C infection * Pregnant or lactating females * Type 1 diabetes or secondary from of diabetes * History or evidence of proliferative diabetic retinopathy or clinically significant neuropathy * Clinically significant hepatic disease * Clinically significant renal impairment * History or evidence of clinically significant cardio-vascular disease or disorder * Acute infection or current malignancy requiring treatment except for excised basal cell carcinoma